Pharma News
05 Oct 2025 to 11 Oct 2025
Oct 11, 2025
Mint Analysis: A Look into Natco's Bold Approach to Patent Challenges
The Delhi High Court has allowed Natco Pharma Ltd to launch a generic version of Roche's Risdiplam, a treatment for spinal muscular atrophy, citing public interest. Natco plans to sell the drug at ₹15,900 per bottle, significantly lower than Roche's price of over ₹6 lakh. Roche may appeal the decision to the Supreme Court.
Oct 11, 2025
Bill Gates and PAHO explore options for making weight-loss medications accessible in low-income nations.
Bill Gates and the Pan American Health Organization are exploring ways to make weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro more accessible in low-income countries. Gates indicated potential support from the Gates Foundation for affordable treatments, while PAHO is developing recommendations to facilitate access and lower costs for these medications.
Oct 11, 2025
CDSCO starts talks on establishing equitable conditions for new drug approvals.
The Central Drugs Standard Control Organization (CDSCO) has begun discussions with stakeholders to create a level playing field in new drug approvals. The aim is to address the cost disparities faced by the first applicant in conducting clinical trials and bioequivalence studies compared to subsequent applicants.
Oct 11, 2025
ARS Pharmaceuticals obtains positive ruling from the EPO regarding the nasal spray 'neffy' for ...
ARS Pharmaceuticals Inc. announced that the European Patent Office upheld the validity of its patent EP 3678649 for nasal spray epinephrine formulations, including Intravail. This follows the successful defense of US patent No. 10,682,414 for treating anaphylaxis with an epinephrine nasal spray. CEO Richard Lowenthal emphasized the strength of their patent portfolio, which is protected until at least 2039.
Oct 10, 2025
Court permits sale of generic version of Roche's drug for rare diseases in India - STAT News
An Indian court has upheld a ruling allowing Natco Pharma to sell a lower-cost generic version of Roche's Evrysdi, a treatment for spinal muscular atrophy. This decision prioritizes public health over corporate profits, as the court recognized the potential benefits of a generic alternative despite not revoking Roche's patents, which expire in 2033 and 2035.
Oct 10, 2025
Roche's defeat in the Delhi High Court opens the door for more affordable treatments for spinal muscular atrophy (SMA).
Oct 10, 2025
Delhi High Court Permits Natco to Market Spinal Muscular Atrophy Medication, Denies Roche's Appeal - Live Law
The Delhi High Court upheld a decision allowing Natco Pharma Ltd to manufacture and sell Risdiplam, a drug for Spinal Muscular Atrophy, despite F Hoffmann-La Roche AG's patent claims. The court found Roche's patent lacked novelty and inventive step, dismissing Roche's appeal and emphasizing the importance of preventing evergreening in pharmaceutical patents.
Oct 10, 2025
Patient advocates and supporters celebrate the Delhi High Court's ruling on SMA medication - Pharmabiz.com
The Delhi High Court has rejected Roche's appeal against Natco Pharma, allowing the introduction of a generic version of the spinal muscular atrophy drug risdiplam. This decision significantly reduces the price from Rs. 6.2 lakh to Rs. 15,900 per bottle, improving access for patients in India. Patient advocates express relief and gratitude for the ruling, emphasizing the importance of affordable lifesaving medicines.
Oct 10, 2025
Delhi High Court permits Indian firm Natco to produce and distribute the Risdiplam medication.
The Delhi High Court upheld a ruling allowing Natco Pharma to produce a generic version of Risdiplam, a drug for spinal muscular atrophy (SMA), despite Roche's patent claims. Natco plans to launch the generic at INR 15,900, significantly lower than Roche's price of around Rs 6 lakh, emphasizing public interest in access to essential medications.
Oct 10, 2025
Editorial - GLP-1 medications have the potential to save the government billions — lawmakers need to take this into consideration.
The U.S. faces a significant obesity crisis, costing $173 billion annually. As Congress considers expanding Medicare coverage for GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), the Congressional Budget Office is urged to adopt dynamic scoring to better assess the broader economic impacts of obesity treatments, which could enhance workforce participation and reduce healthcare costs.
Oct 10, 2025
Gates Foundation and PAHO seek strategies to reduce the cost of weight-loss medications in developing nations.
The Gates Foundation and PAHO are collaborating to make weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro more affordable in low-income countries. With semaglutide set to go off patent next year, generic versions are anticipated. The initiative aims to address obesity's rising global rates and improve access to effective treatments for millions.
Oct 10, 2025
CDSCO requests a comprehensive list of all manufacturers of cough syrups, according to DrugsControl Media Services.
The Central Drugs Standard Control Organisation (CDSCO) has requested all State governments in India to provide a list of cough syrup manufacturers. This move follows a joint audit initiative aimed at ensuring safety, particularly after concerns arose regarding contaminated syrups like Coldrif, Respifresh, and ReLife linked to children's deaths.
Oct 9, 2025
U.S. Generic Pharmaceuticals Market Expected to Hit USD 196.90 Billion by 2034 - BioSpace
The U.S. generic drugs market is projected to grow from $138.24 billion in 2024 to $196.90 billion by 2034, with a CAGR of 3.6%. Key players include Pfizer Inc, Teva Pharmaceuticals, and Aurobindo Pharma. The market is driven by cost-effectiveness and increasing demand for chronic condition treatments, particularly in diabetes and cardiovascular diseases.
Oct 9, 2025
Federal Circuit's Ruling in In re Entresto: A Significant Judgment on After-Arising Issues - Lexology
The Federal Circuit's ruling in In re Entresto (Sacubitril/Valsartan) has significant implications for patent law, particularly regarding "after-arising technology." The court upheld Novartis's patent for Entresto, affirming its validity despite later discoveries of complex drug formulations. The case raises critical questions about patent disclosure requirements, with potential Supreme Court review on the horizon, impacting pharmaceutical patent strategies.
Oct 9, 2025
Gilead has prevented the production of generic versions of its HIV medication for over a decade | Americas
Gilead Sciences has settled patent disputes with generic drug manufacturers, preventing the release of generic versions of its key HIV treatments. Over 80% of HIV patients in the US rely on Gilead's products, solidifying the company's market leadership in the sector.
Oct 9, 2025
Novo plans to acquire Akero for as much as $5.2 billion as part of the new CEO's strategy for revitalization - The Sunday Guardian
Novo Nordisk announced its acquisition of Akero Therapeutics for up to $5.2 billion to access the liver disease drug candidate efruxifermin, currently in late-stage trials for metabolic dysfunction-associated steatohepatitis (MASH). This marks a strategic move by new CEO Mike Doustdar to enhance growth amid market share losses to Eli Lilly. The deal includes an upfront payment of $54 per share.
Oct 9, 2025
Biohacker Bryan Johnson shares unusual side effects experienced from using a weight loss supplement - UNILAD
Tech millionaire Bryan Johnson has halted his microdosing of tirzepatide, the active ingredient in weight-loss drugs Mounjaro and Zepbound, after experiencing increased resting heart rate and decreased sleep quality. Johnson, who aims to reverse his biological age, concluded that the risks outweighed the benefits, although he acknowledged the drug's potential value for others needing metabolic optimization.
Oct 9, 2025
Wockhardt Files New Drug Application with the US FDA for ZAYNICH™ to Treat ...
Wockhardt has submitted a New Drug Application (NDA) to the U.S. FDA for ZAYNICH™ (Zidebactam-Cefepime injection, WCK 5222), aimed at treating serious Gram-negative infections. The application marks a significant step in the development of this novel antibacterial agent.
Oct 9, 2025
AbbVie and Eli Lilly: Who Will Have the Advantage Among Major Pharmaceutical Companies in 2025? - TradingView
Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. pharmaceutical companies with strong portfolios. Lilly's growth is driven by its GLP-1 drugs, Mounjaro and Zepbound, while AbbVie thrives on immunology drugs Skyrizi and Rinvoq. Both companies face challenges but are well-positioned for future growth, with Lilly favored for its high-growth potential in obesity treatments.
Oct 9, 2025
Biogen Directed to Compensate Genentech $88.3 Million for Previous Royalties Related to Cabilly Patents
The U.S. District Court for the Northern District of California has ordered Biogen MA, Inc. to pay Genentech, Inc. $88.3 million in unpaid royalties plus $35.9 million in interest related to the sales of Tysabri, an MS and Crohn's disease treatment. The ruling follows a lawsuit over "tail" royalties after the expiration of Genentech's Cabilly Patents.
Oct 9, 2025
Akari Therapeutics Submits Applications for Two Additional Patents - GlobeNewswire
Akari Therapeutics (Nasdaq: AKTX) has filed two provisional patent applications with the USPTO, protecting its novel immuno-oncology payload PH1 and its combination therapy with other immuno-oncology drugs. These filings aim to enhance Akari's patent portfolio and support the development of first-in-class antibody drug conjugates (ADCs) targeting cancer. The company plans to present its findings at the SITC Congress on November 9th.
Oct 9, 2025
60% of Eligible Early Breast Cancer Patients Are Not Being Treated with CDK4/6 Inhibitors Because of ...
A recent analysis at the Miami Breast Cancer Conference revealed that 60% of eligible early breast cancer patients are not receiving CDK4/6 inhibitors due to access and management barriers. Disparities in treatment between academic and community settings, along with challenges in side effect management and financial obstacles, contribute to this underutilization, impacting patient care and quality of life.
Oct 9, 2025
Delhi High Court affirms decision permitting Natco Pharma to market generic Risdiplam, dismisses Roche's appeal.
The Delhi High Court has ruled in favor of Natco Pharma, allowing it to sell a generic version of Roche's life-saving drug Risdiplam, branded as Evrysdi, for spinal muscular atrophy. The court emphasized public interest, enabling Natco to offer the drug at ₹15,900, significantly lower than Roche's price of over ₹600,000. Roche plans to appeal the decision.
Oct 9, 2025
Akari Therapeutics Submits Provisional Patent Applications for Innovative Immuno-Oncology Solutions...
Akari Therapeutics has filed two provisional patent applications with the USPTO, protecting its novel immuno-oncology payload PH1 and its combination therapy with other immuno-oncology drugs. The PH1 payload, a spliceosome modulator, aims to enhance cancer treatment efficacy. Akari's lead candidate, AKTX-101, targets the Trop2 receptor and shows promise in preclinical studies for improved patient outcomes.
Oct 9, 2025
Novo Nordisk plans to acquire Akero Therapeutics in a deal valued at as much as $5.2 billion - Yahoo Finance
Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion, gaining access to the experimental liver disease drug efruxifermin. The deal includes an upfront payment of $54 per share and an additional $6 per share upon U.S. approval. This move comes as Novo seeks to enhance its portfolio amid competition from Eli Lilly.
Oct 9, 2025
Is It Advisable to Use Weight Loss Medications? Start by Accurately Assessing Obesity - CodeBlue
A surge in weight loss medications, including Novo Nordisk's Ozempic, is prompting new guidelines for obesity diagnosis. The Lancet Diabetes and Endocrinology Commission suggests replacing BMI with body fat measurements for better accuracy. Concerns over side effects and off-label use of these drugs, including cases of stomach paralysis in India, highlight the need for medically supervised treatment.
Oct 9, 2025
Are the new obesity medications financially self-sustaining? - Medical Xpress
A study led by Yale economist Jason Abaluck found that semaglutide drugs, including Ozempic and Wegovy, promote weight loss but may not reduce overall healthcare costs. While linked to health improvements, non-semaglutide expenses increased by about $1,000 annually post-treatment. The findings suggest that insurers may need to negotiate lower prices to manage potential budget impacts.
Oct 9, 2025
Patients seeking weight loss express concerns about FDA restrictions on non-branded medications - The Detroit News
The FDA is cracking down on off-brand weight loss medications like compounded semaglutide and tirzepatide, leaving users anxious about future access. While brand-name drugs such as Ozempic and Zepbound from Novo Nordisk and Eli Lilly are costly, some patients have relied on cheaper alternatives. The FDA's actions may disrupt treatment for many who depend on these medications.
Oct 8, 2025
Sam's Club begins offering Ozempic and Wegovy at reduced prices - USA Today
Sam's Club has joined the list of retailers offering Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, for $499 per month. This price matches that of Costco and includes delivery options. The Danish drugmaker aims to expand access to these GLP-1 medications, which suppress appetite, amid competition from Eli Lilly's Zepbound and Mounjaro.
Oct 8, 2025
Nutriband Submits Temporary Patent Application for Improved Technology - GlobeNewswire
Nutriband Inc. has filed a provisional patent application with the U.S. Patent and Trademark Office to enhance its AVERSA™ abuse-deterrent transdermal technology, aimed at preventing the misuse of opioids and stimulants. This application seeks to improve aversive formulations and coating methods, potentially extending patent protection for its products. The technology is already protected in 46 countries.
Oct 8, 2025
The Rise of Generic Pharmaceuticals: Mexico's Growing Influence in the Global Healthcare Sector
A new report from the IQVIA Institute predicts the global medicines market will reach $2.4 trillion by 2029, driven by generics and biosimilars. Mexico is emerging as a leader in novel drug registrations, with 194 new therapies, highlighting its role in expanding access to affordable healthcare. The shift towards lower-cost treatments is reshaping the pharmaceutical landscape.
Oct 8, 2025
Salipro Biotech expands its international intellectual property portfolio by securing two additional patents in Japan.
Salipro Biotech AB has secured two new patents from the Japanese Patent Office, enhancing its intellectual property in Japan. The patents, focused on Salipro particles and membrane protein extraction, bolster the company's proprietary Salipro platform technology. CEO Jens Frauenfeld emphasized the importance of these patents for collaborations with Japanese pharmaceutical firms, reinforcing Salipro's position in membrane protein innovation.
Oct 8, 2025
China Approves Its Initial Extension for Drug Patent Duration - Mondaq
Boehringer Ingelheim's drug Spevigo IV, a treatment for Generalized Pustular Psoriasis, has received China's first Drug Patent Term Extension (DPTE), extending its patent until December 13, 2036. The extension, granted by the CNIPA, applies to specific claims of patent CN107007833B. This development is significant for innovative drug developers, confirming that biologics can also benefit from DPTE in China.
Oct 8, 2025
Nutriband Inc. Submits Provisional Patent Application to Improve AVERSA™ Abuse Prevention Features
Nutriband Inc. has filed a provisional patent application with the USPTO to enhance its AVERSA™ abuse-deterrent transdermal technology, aimed at preventing the misuse of opioids and stimulants. The application focuses on improved aversive formulations and coating methods, potentially extending patent protection for its products. AVERSA™ technology is designed to improve safety while ensuring accessibility for patients in need.
Oct 8, 2025
Major Pharmaceuticals Approaching Patent Expiration: Market Analysis, Projections, and 6.1% CAGR
The Global Blockbuster Drugs on Patent Cliffs Market is projected to reach USD 258.6 billion by 2034, growing at a CAGR of 6.1%. Major drugs like Humira (AbbVie), Keytruda (Merck), and Ozempic (Novo Nordisk) face patent expirations, creating opportunities for biosimilars and generics. This shift is expected to redefine pharmaceutical pricing and competition, particularly in oncology and immunology sectors.
Oct 8, 2025
The Hidden Toxic Legacy of Ozempic - Popular Mechanics
David Mendosa, diagnosed with type 2 diabetes and obesity, found success with Byetta, a GLP-1 agonist derived from Gila monster venom. Approved in 2005, Byetta helped him lose significant weight and manage his diabetes. This paved the way for other GLP-1 medications like Ozempic and Wegovy, revolutionizing diabetes treatment and weight loss. Eli Lilly is now testing a new oral GLP-1 drug, orforglipron.
Oct 8, 2025
Protagonist Therapeutics' Icotrokinra: A Potential Game-Changer with Extensive Applications...
Analyst Yun Zhong from Wedbush has maintained a Buy rating on Protagonist Therapeutics, setting a price target of $70.00, citing the potential of icotrokinra for inflammatory bowel disease (IBD) and its favorable safety profile. H.C. Wainwright also reiterated a Buy rating with an $80.00 target, despite negative insider sentiment regarding the stock.
Oct 7, 2025
How Merck's Biotech Advantage Fuels Dow Jones Increases | Disruption Banking
Merck & Co. (MRK), the first pharmaceutical company in the Dow Jones Industrial Average since 1979, has evolved significantly, driven by innovations like Keytruda, its leading cancer drug. Despite facing challenges, including patent expirations and regulatory scrutiny, Merck maintains a strong dividend and a promising pipeline, positioning itself as a key biotech player in the index.
Oct 7, 2025
Major medication sparks debate over scientific colonialism - The Hindu
The antibiotic rapamycin, discovered in 1964 during the Medical Expedition to Easter Island (METEI), has become a billion-dollar success in pharmaceuticals, particularly as an immunosuppressant. However, its history raises ethical concerns about scientific colonialism and Indigenous rights, as the Rapa Nui people have not benefited from its commercialization despite their crucial role in its discovery.
Oct 7, 2025
Eli Lilly plans to allocate $1 billion for contract manufacturing in India - The Business Times
Eli Lilly plans to invest over $1 billion in India to enhance its contract manufacturing capabilities, including a new manufacturing and quality center in Hyderabad. This investment follows President Trump's announcement of a 100% tariff on imported branded drugs. Eli Lilly aims to leverage India's skilled workforce to support its global supply network and expand its operations.
Oct 7, 2025
DEG Found in Relife and Respifresh Cough Syrup in Madhya Pradesh, Reports DrugsControl Media Services
Madhya Pradesh food and drugs administration has identified Relife and Respifresh cough syrups as "unsafe" due to high levels of diethylene glycol (DEG), a toxic chemical. This follows earlier concerns regarding Coldrif syrup. The findings raise significant health risks associated with these products.
Oct 7, 2025
Amgen Launches Innovative DTC Initiative and Reduces Cholesterol Medication Cost by 60% - TradingView
Amgen (AMGN) has launched a direct-to-consumer program, AmgenNow, offering its cholesterol drug Repatha at a discounted price of $239 per month, nearly 60% lower than its U.S. list price. This initiative aims to assist uninsured patients and those on high-deductible plans. The program aligns with political pressures for lower drug prices and follows Amgen's significant investments in U.S. manufacturing.
Oct 7, 2025
Are the New Obesity Medications Cost-Effective? | Yale Insights
A study led by Yale economist Jason Abaluck highlights the health benefits of semaglutide, marketed as Ozempic and Wegovy, for obesity treatment. While linked to weight loss and improved health outcomes, the drugs may not reduce overall healthcare costs, with expenses rising by about $1,000 annually post-treatment. Abaluck urges broader adoption but cautions about potential budget impacts for insurers.
Oct 7, 2025
Novo Nordisk Reduces Workforce at Major U.S. Facility During Worldwide Reorganization - Modern Diplomacy
Novo Nordisk, the maker of Wegovy and Ozempic, has begun layoffs at its Clayton, North Carolina manufacturing site as part of a global restructuring plan under new CEO Mike Doustdar. The company aims to cut 9,000 jobs worldwide amid rising competition and slower sales growth. Despite the layoffs, Novo Nordisk is expanding its North Carolina plant to support future production.
Oct 7, 2025
Novo Nordisk reduces workforce in production roles at its facility in the United States - RTE
Novo Nordisk has laid off dozens of employees at its Clayton, North Carolina plant, which produces semaglutide for its weight-loss drug Wegovy and diabetes drug Ozempic. This move is part of a global restructuring plan under new CEO Mike Doustdar, which includes 9,000 job cuts to reduce costs amid slowing sales growth and increased competition from Eli Lilly.
Oct 7, 2025
Novo Nordisk reduces production line positions at important US facility, documents reveal.
Novo Nordisk, the maker of Wegovy and Ozempic, has laid off dozens of employees at its Clayton, North Carolina manufacturing site as part of a global restructuring plan under new CEO Mike Doustdar. The cuts, part of a larger 9,000 job reduction, aim to streamline operations amid increasing competition from Eli Lilly. The company is also expanding the facility with a $4.1 billion investment.
Oct 7, 2025
NHRC sends notice to three states and DCGI regarding fatalities linked to cough syrup.
The National Human Rights Commission (NHRC) has issued notices to the governments of Madhya Pradesh, Rajasthan, and Uttar Pradesh, urging investigations into children's deaths linked to contaminated cough syrup. The NHRC has also called for an immediate ban on the sale of spurious medicines in these states.
Oct 7, 2025
Novo Nordisk's Legal Challenges Against CMS's Single Source Drug Decisions Encounter IRA Restrictions
The U.S. Court of Appeals for the Third Circuit upheld the Medicare Drug Price Negotiation Program under the Inflation Reduction Act, rejecting Novo Nordisk's challenge regarding the classification of its six insulin products, including Fiasp and NovoLog, as a single drug. The court affirmed that judicial review is barred under the IRA, marking another defeat for pharmaceutical companies.
Oct 7, 2025
Wockhardt Fails to Obtain NPPA Approval for Nafithromycin, Raises Concerns Over Patent Validity
The Multidisciplinary Committee of Experts reviewed Wockhardt Limited's application for exemption of Nafithromycin Tablets, a patented non-scheduled formulation, during its 71st meeting. The committee requested verification from CDSCO and CGPDTM regarding the formulation's patent status. Nafithromycin, launched in November 2024, targets drug-resistant Community-Acquired Bacterial Pneumonia and is crucial in combating antimicrobial resistance.
Oct 7, 2025
ACB apprehends DCA Assistant Director, Drug Inspector, and a private individual for soliciting bribes...
The Anti-Corruption Bureau (ACB) arrested DCA Assistant Director Maryala Srinivasulu and Drug Inspector Karthik Bhardwaj for allegedly demanding and accepting a bribe of Rs 20,000 from Vijetha hospital in Karimnagar. The operation took place on October 7, 2025, highlighting ongoing corruption issues within the drug regulatory framework.
Oct 7, 2025
Autoinjector Market Projected to Reach USD 6.21 Billion by 2033, According to OpenPR.com
The global autoinjectors market is projected to grow from USD 1.88 billion in 2024 to USD 6.21 billion by 2032, with a CAGR of 18.23%. Factors driving this growth include patient preference for self-injections, rising demand for biosimilars, and increasing chronic disease prevalence. Key players include Eli Lilly, AbbVie, and Pfizer.
Oct 7, 2025
Medication costs expected to increase by 10% following the conclusion of patent exemption.
Bangladesh is set to graduate from Least Developed Country status in November 2026, which will end its TRIPS waiver, impacting the pharmaceutical industry. Experts warn that drug prices could rise significantly, with insulin costs potentially increasing eightfold. Incepta Pharmaceuticals' Abdul Muktadir highlighted that without the waiver, local production of patented drugs will be severely restricted, leading to higher costs for consumers.
Oct 6, 2025
Amgen Introduces Direct-to-Patient Initiative Providing Repatha at a 60% Reduced Price
Amgen has launched a direct-to-patient program for its cholesterol drug Repatha, offering it at nearly a 60% discount to U.S. patients. This initiative comes in response to the Trump administration's efforts to reduce drug prices.
Oct 6, 2025
Aspire Submits Comprehensive Patent for Sublingual Administration | ASBP Stock Update
Aspire Biopharma Holdings, Inc. has filed an omnibus patent application with the U.S. Patent and Trademark Office for its innovative sublingual drug delivery platform. This technology aims to enhance the bioavailability and speed of onset of Active Pharmaceutical Ingredients (APIs), addressing key challenges in drug delivery. The application reflects Aspire's commitment to securing intellectual property for its advancements in healthcare.
Oct 6, 2025
Aspire Biopharma submits patent application for its sublingual drug delivery system - TipRanks
Aspire Biopharma (ASBP) has filed an omnibus patent application with the U.S. Patent and Trademark Office for its advanced sublingual drug delivery technology. This application aims to protect the company's proprietary system, which enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients, improving bioavailability and speed of onset.
Oct 6, 2025
Alkermes Hit with Antitrust Lawsuit for Allegedly Trying to Prevent Generic Vivitrol from Entering the Market
Alkermes plc is facing a proposed class-action lawsuit from Value Drug Company, alleging the company illegally blocked generic versions of its opioid and alcohol dependence treatment, Vivitrol. The lawsuit claims Alkermes engaged in fraudulent patent tactics and anticompetitive settlements with Teva Pharmaceuticals and Amneal Pharmaceuticals, delaying generic market entry and inflating prices for U.S. purchasers.
Oct 6, 2025
Costco's pharmacy has begun offering weight loss medications Ozempic and Wegovy - USA Today
Costco is now offering discounted prices on Novo Nordisk's weight-loss drugs, Wegovy and Ozempic, at $499 for self-pay members. Executive members and Citibank Visa cardholders can receive an additional 2% discount. Despite competition from Eli Lilly's Zepbound and Mounjaro, Novo Nordisk aims to improve access to these GLP-1 medications, which are often not covered by employer insurance for obesity.
Oct 6, 2025
Recently, appetite-suppressing hormones have gained significant attention due to the launch of ...
Recent blockbuster weight-loss drugs have brought attention to appetite-suppressing hormones, highlighting their role in obesity treatment. These advancements in pharmacotherapy are reshaping approaches to weight management and obesity-related health issues.
Oct 6, 2025
ESPR Resolves Patent Dispute Over Nexletol/Nexlizet with RDY, Shares Rise - sharewise
Esperion Therapeutics (ESPR) has settled patent litigation with Dr. Reddy’s Laboratories (RDY) regarding its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The agreement prevents RDY from launching generics in the U.S. before April 19, 2040. Following the announcement, Esperion's shares rose 13.8%, reflecting strong sales growth for its products.
Oct 6, 2025
Is AstraZeneca capable of sustaining its growth? - Investors' Chronicle
Pharmaceutical stocks surged following the US government's first 'most favoured nation' pricing agreement with Pfizer. AstraZeneca's shares rose 11%, boosting its market capitalization to £193bn and restoring its top position on the London Stock Exchange. The company plans a direct listing in New York to strengthen its US presence, where it generates 40% of its revenue.
Oct 6, 2025
Trends and Changing Standards of Injunctions in Pharmaceutical Patent Litigation in Indian Courts
Indian courts are increasingly balancing patent rights with public health needs in pharmaceutical injunction cases. Recent rulings, including those involving drugs like Erlotinib and Sorafenib, emphasize the importance of access to affordable medicines. The judiciary's nuanced approach reflects India's role as a major generic drug supplier while fostering innovation, shaping a unique landscape in intellectual property law.
Oct 6, 2025
Investigation of Spray Drying Techniques for the Stabilization of Peptides, Oligonucleotides, and More...
Pharmaceutical developers are set to explore spray drying technology to enhance the stability and manufacturability of peptides, oligonucleotides, and monoclonal antibodies. The upcoming session will cover innovations in spray drying, formulation strategies, and methods to maintain molecular integrity, aiming to optimize production workflows for various pharmaceutical compounds.
Oct 6, 2025
ESPR Reaches Settlement in Nexletol/Nexlizet Patent Dispute with RDY, Shares Rise - TradingView
Esperion Therapeutics (ESPR) has settled patent litigation with Dr. Reddy’s Laboratories (RDY) regarding its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The agreement prevents RDY from launching generics in the U.S. before April 19, 2040. Following the announcement, Esperion's shares rose 13.8%, reflecting strong market confidence in its products.
Oct 6, 2025
ESPR Reaches Settlement in Nexletol/Nexlizet Patent Dispute with RDY, Shares Rise - Yahoo Finance
Esperion Therapeutics (ESPR) has settled patent litigation with Dr. Reddy’s Laboratories (RDY) regarding its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The agreement prevents RDY from launching generics in the U.S. before April 19, 2040. Following the announcement, Esperion's shares rose 13.8%, reflecting strong sales growth for its products.
Oct 6, 2025
MP Intensifies Efforts for Accountability in Coldrif Cough Syrup Incident - Drugs Control Media Services
Madhya Pradesh has suspended Deputy Drugs Controller Shobhit Kosta and two drugs inspectors in response to the deaths of 14 children linked to contaminated Coldrif cough syrup. This action aims to enhance accountability and address regulatory failures in the pharmaceutical oversight following the tragic incident.
Oct 6, 2025
Eli Lilly plans to enhance its manufacturing and supply capabilities in India through a $1 billion investment - Irish Examiner
Eli Lilly announced a $1 billion investment in India to enhance manufacturing and supply through local drugmakers, aiming to increase availability of key drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune conditions. The company is also launching a manufacturing facility in Hyderabad and expanding its contract manufacturing network amid rising competition from generic drugmakers.
Oct 6, 2025
Eli Lilly invests $1 billion to enhance manufacturing in India - NewsBytes
Eli Lilly plans to invest over $1 billion in India to enhance local manufacturing and supply capabilities for key drugs, including those for obesity, diabetes, and Alzheimer's. This investment is part of Eli Lilly's global expansion strategy, as the company aims to strengthen its production capacity amid US tariff concerns. Currently, Eli Lilly relies on contract manufacturers in India.
Oct 6, 2025
Eli Lilly Allocates $1 Billion for Pharmaceutical Production in India - Insights and Data - IndexBox
Eli Lilly announced a $1 billion investment in India to enhance manufacturing and supply of its key drugs, including Mounjaro for obesity and treatments for diabetes and Alzheimer's. The company is collaborating with local drugmakers and establishing a facility in Hyderabad. This move aligns with global efforts to boost manufacturing capacity amid rising competition from generic drugmakers.
Oct 6, 2025
D.C. Circuit Court Affirms That Generic Drug Manufacturers Can Exclude Patented Uses from Their Labels
The D.C. Circuit Court has upheld the legality of the "skinny label" practice, allowing generic drugmakers to omit patented uses from their labels. This ruling supports generic manufacturers in marketing non-patented indications while avoiding patent infringement, impacting future patent litigation and FDA labeling policies in the pharmaceutical industry.
Oct 6, 2025
Nobel Prize in Medicine awarded to three researchers for discovering the immune system's 'defense mechanisms' - Griffon News
Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi won the Nobel Prize in Medicine for their groundbreaking research on regulatory T-cells, which help prevent autoimmune diseases. Their discoveries have paved the way for potential treatments for autoimmune disorders and cancer. The trio will receive their award on December 10, with a total prize of $1.2 million.
Oct 6, 2025
Evolv introduces a peptide that activates GLP-1 receptors, marking the emergence of a new category of 'biomimetics.'
Evolv has launched a new dietary supplement, Evolv GLP-1, made from engineered baker's yeast to mimic appetite-regulating hormones GLP-1 and GIP. Unlike traditional supplements, it has a half-life of 1-2 days, offering a middle ground between quick-acting supplements and long-lasting injectable drugs like Ozempic. A 90-day human clinical study is currently underway.
Oct 6, 2025
J&J's Innovative Medicines Division is Well-Positioned Before Q3 Earnings Report
Johnson & Johnson (JNJ) anticipates stronger sales growth in its Innovative Medicine segment for the second half of 2025, despite challenges from the loss of exclusivity for Stelara and the Medicare Part D redesign. Key products like Darzalex, Tremfya, and Erleada are expected to drive growth, while competition from biosimilars and generics may hinder performance. JNJ's shares have risen 30.5% year-to-date.
Oct 6, 2025
Eli Lilly plans to invest more than $1 billion in India to enhance its manufacturing capabilities.
Eli Lilly plans to invest over $1 billion in India to enhance manufacturing and supply through local drugmakers, focusing on key drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune conditions. The company aims to expand its presence with a new facility in Hyderabad and is actively engaging with contract manufacturers. This move follows a $5 billion investment in U.S. manufacturing.
Oct 6, 2025
Costco Pharmacy will provide Ozempic and Wegovy for a monthly fee of $499 - Mass Market Retailers
Costco is expanding its pharmacy offerings by adding weight-loss drugs Ozempic and Wegovy, priced at $499 monthly for members. This move positions Costco alongside CVS and Walmart in the growing GLP-1 market. Novo Nordisk, the manufacturer, confirmed availability at over 500 locations, aiming to enhance access to these popular medications amid rising consumer demand.
Oct 5, 2025
Ozempic is now available in India, but its origins trace back to experiments conducted in the 1970s: The story of its development.
Novo Nordisk is set to launch its blockbuster drug Ozempic (semaglutide) in India, aimed at aiding millions with Type 2 diabetes. The once-weekly injectable, known for its blood sugar management and weight loss benefits, marks a significant expansion in treatment options for patients. This development was confirmed by Vikrant Shrotiya, the company's India Head.
Oct 5, 2025
Opening the path": Could a crucial medication resolve ongoing patent litigation disputes?
A recent ruling clarifies that in Indian patent law, a generic's failure to "clear the way" does not establish a prima facie case for injunctions. The court emphasized that the validity of a patent cannot be presumed, and such failures should only be considered when assessing the balance of convenience, as seen in cases involving AstraZeneca AB and Torrent Pharmaceuticals Limited.
Oct 5, 2025
India: Three states prohibit cough syrup following the deaths of multiple children - DW
The Indian Health Ministry has banned Coldrif cough syrup, produced by Sresan Pharma, after tests revealed it contained toxic diethylene glycol (DEG), linked to the deaths of at least nine children. Madhya Pradesh, Tamil Nadu, and Kerala have halted its sale, raising concerns over India's pharmaceutical industry, which has faced scrutiny following previous incidents involving contaminated medicines.
Oct 5, 2025
Costco Amazes Customers by Offering Wegovy and Ozempic at Half Price
Costco has partnered with Novo Nordisk to offer weight-loss drugs Wegovy and Ozempic at a reduced price of $499 for a four-week supply, significantly lower than their typical costs. However, a doctor's prescription is required, and the discount is only available for self-paying members. This initiative aims to improve access to these medications amid ongoing insurance coverage challenges.
Oct 5, 2025
Costco Teams Up with Novo Nordisk to Offer Ozempic and Wegovy | TopNews
Costco has partnered with Novo Nordisk to offer discounted pricing on semaglutide injectables, Ozempic and Wegovy, at its U.S. pharmacies. Starting October 3, eligible members can purchase a one-month supply for $499, significantly lower than typical retail prices. This initiative aims to improve access to diabetes and obesity treatments while addressing broader issues of drug affordability and healthcare delivery in the U.S.
